Ponatinib: A third-generation inhibitor for the treatment of CML

Recent Results in Cancer Research

Volumn 201, Issue , 2015, Pages 99-107

  Wehrle, Julius ^a   Pahl, Heike L ^a   Bubnoff, Nikolas Von ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BCR ABL GENE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; ENZYME INHIBITION; EUROPE; GENE MUTATION; HUMAN; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNITED STATES; WILD TYPE; ANIMAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84906924095     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_5     Document Type: Article

References (32)

1. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1):276–283
2. Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114(27):5426–5435
3. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al (2012a) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075–2088
4. Cortes J, Kim D-W, Pinilla-Ibarz J, le Coutre P, Chuah C, Nicolini F, et al (2012b) A pivotal phase 2 trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12 month follow up of the PACE trial. Blood 120 ([Abstract 163] presented at ASH meeting 2012 in Atlanta)
5. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi J-F, Goldberg GA et al (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25(6):481–496
6. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26(20):3358–3363
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037
8. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417
9. Falco VD, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, et al. (2013) Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab (Internet). 2013 Mar 22 (cited 2013 Apr 29); Available from: http://jcem.endojournals.org/content/early/2013/03/21/jc.2012-2672
10. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K et al (2003) Genotypephenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African–American men and women. Pharmacogenetics 13(10):595–606
11. Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK et al (2011) Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 10(6):1028–1035
12. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI et al (2012) Ponatinib (AP24534), a multitargeted Pan-FGFR inhibitor with activity in multiple FGFRamplified or mutated cancer models. Mol Cancer Ther 11(3):690–699
13. Jain P, Kantarjian H, Cortes J (2013) Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol 14(2):127–143
14. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540–3546
15. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260–2270
16. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 12(9):841–851
17. Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K et al (1990) Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis. Br J Haematol 74(1):24–29
18. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S et al (2005) Response and resistance in 300 patients with BCR-ABL–positive leukemias treated with imatinib in a single center. Cancer 103(8):1659–1669
19. Mahon F-X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6):2368–2373
20. Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud J-P, Hayette S (2007) BCR-ABL mutant kinetics in CML patients treated with dasatinib. Leuk Res 31(6):865–868
21. O’Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110(7):2242–2249
22. O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al (2009) AP24534, a pan- BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401–412
23. Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M et al (2012) Three novel patient-derived BCR-ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87(11):E125–E128
24. Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al (2010) Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259
25. Shah NP, Sawyers CL (2003) Mechanisms of resistance to STI571 in Philadelphia chromosomeassociated leukemias. Oncogene 22(47):7389–7395
26. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia- positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 12(24):7374–7379
27. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215
28. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24): 2531–2541
29. Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12):3739–3745
30. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P et al (2005) A cellbased screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105(4):1652–1659
31. Zhou T, Commodore L, Huang W-S, Wang Y, Thomas M, Keats J et al (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1):1–11
32. Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer F-D, Hochhaus A et al (2012) Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol 157(4):483–492